Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity

NCT07423481 | Not Yet Recruiting

• 2 other identifiers: RC25_04462026-A00299-42
• Study Type: observational
• Target: 3,000
• Locations: 1 country
• Sites: 1

Brief Summary

SEMAFOLLOW is a real-world follow-up study examining the outcomes of individuals treated with WEGOVY® (semaglutide 2.4 mg) under the temporary authorisation for use (ATU) and early access programme in France. This study evaluates weight change, treatment strategies and well-being, drawing on the expertise of teams from various specialist obesity centres in France.

Conditions

Obesity & Overweight

Keywords

WEGOVY®; sémaglutide 2,4 mg; Obesity; Overweight; ATU

Outcome Measures

Primary Outcomes (1)

• Describe weight changes during the follow-up period according to patient characteristics.

  Baseline

Secondary Outcomes (3)

• Identify the characteristics of patients who continue treatment or switch to other obesity management strategies and the associated factors.

  Baseline

• Compare the profiles of responders and non-responders

  Baseline

• Describe weight change according to different subpopulations.

  Baseline

Study Arms (1)

SEMAFOLLOW study population

Patient agreeing to participate in the SEMAFOLLOW study.

Other: SEMAFOLLOW questionnaire

Interventions

SEMAFOLLOW questionnaire OTHER

If the patient agrees, the center will send a link to the questionnaires via email. Patients who have completed the questionnaires will be analyzed in the SEMAFOLLOW study. Estimated time to complete the questionnaire: approximately 30 minutes

SEMAFOLLOW study population

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients treated with WEGOVY® (semaglutide 2.4 mg) under temporary authorization for use (ATU) and the early access program in France.

You may qualify if:

• Patients included in the ATU/early access program for WEGOVY with at least two dispenses of WEGOVY
• No objection to the use of their data
• Patients able to complete an online questionnaire (via the internet)

You may not qualify if:

• Protected patients: minors, adults under guardianship, conservatorship, and/or legal protection

Sponsors & Collaborators

• Nantes University Hospital: lead
• Novo Nordisk A/S: collaborator

Study Sites (1)

Nantes university hospital

Nantes, France

Location

MeSH Terms

Conditions

Obesity; Overweight

Condition Hierarchy (Ancestors)

Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Officials

• David JACOBI

  Nantes University Hospital

  STUDY DIRECTOR

Central Study Contacts

David JACOBI

CONTACT

+332 53 48 28 35; David.Jacobi@univ-nantes.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 13, 2026
• First Posted: February 20, 2026
• Study Start (Estimated): June 1, 2026
• Primary Completion (Estimated): March 1, 2027
• Study Completion (Estimated): March 1, 2027
• Last Updated: May 13, 2026

Record last verified: 2026-05

Locations

FR (1)